60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Sell (E+)” Rating from Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Down 14.6 %

Shares of SXTP opened at $0.62 on Friday. The company has a 50-day moving average price of $1.16 and a two-hundred day moving average price of $1.07. The stock has a market cap of $1.43 million, a price-to-earnings ratio of -0.06 and a beta of 4.24. 60 Degrees Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $7.20.

Insiders Place Their Bets

In related news, CEO Geoffrey S. Dow bought 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were bought at an average cost of $1.27 per share, for a total transaction of $45,495.21. Following the completion of the transaction, the chief executive officer now owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have purchased a total of 66,372 shares of company stock valued at $82,410 in the last 90 days. 10.27% of the stock is currently owned by insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.